BioCentury
ARTICLE | Company News

Allergan, Teva generics news

August 8, 2016 7:00 AM UTC

Teva completed its acquisition of Allergan’s global generic pharmaceuticals business for $33.4 billion in cash and about 100 million Teva shares. The shares are valued at about $5.4 billion based on T...